Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

Journal of the American Academy of Child and Adolescent Psychiatry
W Burleson DavissCAT STUDY TEAM

Abstract

To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD). In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30). Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing). Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs. There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes. There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes. Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal. Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks. Clonidine, used alone or wit...Continue Reading

References

Oct 31, 1977·JAMA : the Journal of the American Medical Association·L E Kibler, P C Gazes
Apr 1, 1991·Archives of General Psychiatry·J F LeckmanD J Cohen
Nov 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·K S Chandran
Feb 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·S RubinsteinW L Licamele
Mar 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·T E WilensT Spencer
Mar 1, 1993·Journal of the American Academy of Child and Adolescent Psychiatry·R SteingardA Gonzalez
Apr 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·D P CantwellD F Connor
May 7, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·T E WilensD Cantwell
Oct 3, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·L KofoedR Shapiro
Dec 22, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·D F ConnorJ M Swanson
Mar 4, 2000·JAMA : the Journal of the American Medical Association·J M ZitoF Lynch
Feb 28, 2002·Neurology·UNKNOWN Tourette's Syndrome Study Group
May 17, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Mark OlfsonPeter S Jensen
Jul 23, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Philip L Hazell, John E Stuart
Jun 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Steven Pliszka, UNKNOWN AACAP Work Group on Quality Issues
Jan 10, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Donna R PalumboUNKNOWN CAT STUDY TEAM

❮ Previous
Next ❯

Citations

Mar 30, 2011·European Child & Adolescent Psychiatry·Veit RoessnerUNKNOWN ESSTS Guidelines Group
Jun 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark A SteinLaura Hlavaty
Jun 13, 2009·Journal of Child and Adolescent Psychopharmacology·Floyd R SalleeJames J McGough
Nov 3, 2009·Journal of Child and Adolescent Psychopharmacology·Michael CannonW Burl Daviss
Jun 11, 2010·Journal of Developmental and Behavioral Pediatrics : JDBP·Daniel F ConnorKeith McBurnett
Aug 20, 2014·Current Psychiatry Reports·Benjamin N Schneider, Michael Enenbach
Mar 15, 2012·Expert Opinion on Drug Metabolism & Toxicology·Sophie DuongSharon B Wigal
Oct 20, 2009·Child and Adolescent Psychiatric Clinics of North America·Judith A Owens, Sricharan Moturi
Jul 25, 2009·Journal of the American Academy of Child and Adolescent Psychiatry·Michael H BlochJames F Leckman
Nov 10, 2011·Pediatric Annals·Karen Pierce
May 30, 2009·Pharmacotherapy·Julie A Dopheide, Steven R Pliszka
Mar 18, 2011·British Journal of Pharmacology·Catharine A Winstanley
Jan 9, 2013·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Samuele CorteseUNKNOWN European ADHD Guidelines Group
Sep 16, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Hwee Min D LeeAndis Graudins
Dec 20, 2011·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensSharon Youcha
Jul 28, 2016·Journal of the American Academy of Child and Adolescent Psychiatry·James T McCrackenRobert M Bilder
Sep 30, 2010·Journal of Attention Disorders·Michael J ManosPeter S Jensen
Jul 7, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Tiene BautersGeneviève Laureys
Nov 26, 2015·The Cochrane Database of Systematic Reviews·Ole Jakob StorebøChristian Gluud
Feb 21, 2018·European Child & Adolescent Psychiatry·Sarah C O S PadilhaRoberto Pontarolo
Jun 4, 2010·Critical Care Medicine·Brian J Barnes, James M Hollands
Jun 30, 2018·Molecular Psychiatry·Arthur CayeLuis Augusto Rohde
Apr 7, 2017·Therapeutic Advances in Drug Safety·Jose Martinez-RagaEloisa Carabal
Mar 25, 2016·Journal of Developmental and Behavioral Pediatrics : JDBP·Stephen P BeckerJeffery N Epstein
Sep 8, 2020·Seminars in Pediatric Neurology·David Q Beversdorf
Jan 10, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Donna R PalumboUNKNOWN CAT STUDY TEAM
Nov 11, 2021·European Child & Adolescent Psychiatry·Veit RoessnerKerstin J Plessen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.